With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1228779-96-1,3-Nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide,as a common compound, the synthetic route is as follows.
To a solution of 3- ((1H-pyrrolo [2, 3-b] pyridin-5-yl) oxy) -4′- ((4′-chloro-5,5-dimethyl-3, 4, 5, 6-tetrahydro- [1, 1′-biphenyl] -2-yl) methyl) – [1, 1′-biphenyl] -4-carboxylic acid (30 mg, 0.0533 mmol) in DCM (50 mL) was added HATU (30.4 mg, 0.08 mmol) and triethylamine (27 mg, 0.267 mmol). The mixture was stirred at room temperature for 1 hour. Then to the mixture were added 3-nitro-4- (((tetrahydro-2H-pyran-4-yl) methyl) amino) benzenesulfonamide (33.6 mg, 0.107 mmol). The mixture was stirred at room temperature for overnight. The mixture was washed with brine, dried over Na 2SO 4, concentrated and purified by chromatography column on silica (eluent: EA/PE = 1/1 then MeOH/DCM = 1/10) to give the crude product. The crude product was further purified by prep-TLC (MeOH/DCM = 1/20) to give the product (1.79 mg, 3.9%). 1H NMR (400 MHz, DMSO-d 6) delta ppm: 12.35 (s, 1H), 11.73 (s, 1H), 8.68-8.50 (m, 2H), 8.10-8.02 (m, 1H), 7.84 (d, J = 8.0 Hz, 1H), 7.67-7.56 (m, 2H), 7.56-7.48 (m, 1H), 7.43 (d, J = 8.0 Hz, 3H), 7.37 (d, J = 8.2 Hz, 2H), 7.17 (d, J = 8.2 Hz, 2H), 7.10 (d, J = 8.0 Hz, 2H), 6.99 (s, 1H), 6.40 (s, 1H), 5.41-5.21 (m, 1H), 3.85 (d, J = 8.5 Hz, 2H), 3.28-3.15 (m, 6H), 2.07-1.94 (m, 4H), 1.94-1.79 (m, 3H), 1.67-1.54 (m, 2H), 1.38-1.31 (m, 2H), 0.91 (s, 6H). MS (ESI, m/e) [M+1] + 860.1.
1228779-96-1, 1228779-96-1 3-Nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide 57474953, aTetrahydropyrans compound, is more and more widely used in various fields.
Reference£º
Patent; BEIGENE, LTD.; GUO, Yunhang; XUE, Hai; WANG, Zhiwei; SUN, Hanzi; (493 pag.)WO2019/210828; (2019); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics